Sesen Bio Inc. [SESN] is -37.10% lower this YTD. Is it still time to buy?


Sesen Bio Inc. [NASDAQ: SESN] price surged by 29.97 percent to reach at $0.12. The company report on May 3, 2022 that Sesen Bio Provides Strategic Update.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it has initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of the Company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of the Company’s proprietary technologies. Pending any decision to undertake any strategic alternative, the Company is continuing its development activities in accordance with its existing business strategy.

“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio. “As we assess potential external strategic alternatives, we continue to seek to create value through the development of Vicineum for the treatment of non-muscle invasive bladder cancer. We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial.”.

A sum of 68405108 shares traded at recent session while its average daily volume was at 1.85M shares. Sesen Bio Inc. shares reached a high of $0.56 and dropped to a low of $0.435 until finishing in the latest session at $0.51.

The one-year SESN stock forecast points to a potential upside of 72.43. The average equity rating for SESN stock is currently 2.30, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Sesen Bio Inc. [SESN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SESN shares is $1.85 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SESN stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Sesen Bio Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on August 16, 2021. The new note on the price target was released on June 11, 2019, representing the official price target for Sesen Bio Inc. stock.

The Average True Range (ATR) for Sesen Bio Inc. is set at 0.05, with the Price to Sales ratio for SESN stock in the period of the last 12 months amounting to 3.91. The Price to Book ratio for the last quarter was 0.60, with the Price to Cash per share for the same quarter was set at 0.80.

SESN Stock Performance Analysis:

Sesen Bio Inc. [SESN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 24.48. With this latest performance, SESN shares dropped by -14.64% in over the last four-week period, additionally sinking by -57.64% over the last 6 months – not to mention a drop of -82.32% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SESN stock in for the last two-week period is set at 51.16, with the RSI for the last a single of trading hit 59.85, and the three-weeks RSI is set at 46.88 for Sesen Bio Inc. [SESN]. The present Moving Average for the last 50 days of trading for this stock 0.5794, while it was recorded at 0.4152 for the last single week of trading, and 1.1227 for the last 200 days.

Insight into Sesen Bio Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Sesen Bio Inc. [SESN] shares currently have an operating margin of -106.09 and a Gross Margin at +99.68. Sesen Bio Inc.’s Net Margin is presently recorded at -1.27.

Return on Equity for this stock declined to -0.41, with Return on Assets sitting at -0.13.

Sesen Bio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 17.80 and a Current Ratio set at 17.80.

Sesen Bio Inc. [SESN] Insider Position Details

There are presently around $21 million, or 24.70% of SESN stock, in the hands of institutional investors. The top three institutional holders of SESN stocks are: BLACKROCK INC. with ownership of 13,488,604, which is approximately 23.349% of the company’s market cap and around 0.90% of the total institutional ownership; VANGUARD GROUP INC, holding 12,366,756 shares of the stock with an approximate value of $4.87 million in SESN stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $1.78 million in SESN stock with ownership of nearly 72.14% of the company’s market capitalization.

43 institutional holders increased their position in Sesen Bio Inc. [NASDAQ:SESN] by around 11,012,293 shares. Additionally, 52 investors decreased positions by around 10,972,480 shares, while 26 investors held positions by with 31,050,622 shares. The mentioned changes placed institutional holdings at 53,035,395 shares, according to the latest SEC report filing. SESN stock had 15 new institutional investments in for a total of 1,212,138 shares, while 26 institutional investors sold positions of 3,486,290 shares during the same period.